Kinnate Biopharma

About:

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers.

Website: https://www.kinnate.com

Top Investors: Fidelity, RA Capital Management, OrbiMed, Viking Global Investors, Janus Henderson Investors

Description:

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

Total Funding Amount:

$195M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

San Diego, California, United States

Founded Date:

2018-01-01

Founders:

Eric A Murphy, Stephen Kaldor

Number of Employees:

51-100

Last Funding Date:

2020-08-26

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai